Last updated: February 20, 2026
What is the current market landscape for TYLENOL W/ CODEINE NO. 2?
TYLENOL W/ CODEINE NO. 2 combines acetaminophen and codeine, classified as a Schedule III controlled substance. Its primary use is pain relief for moderate to severe pain, often prescribed when other analgesics are insufficient. The drug's market presence has declined over recent years, driven by regulatory restrictions, the opioid crisis, and shifting prescribing patterns.
How does regulatory environment influence its market?
The Drug Enforcement Administration (DEA) classifies TYLENOL W/ CODEINE NO. 2 as a Schedule III substance under the Controlled Substances Act. Federal regulations stipulate strict manufacturing, distribution, and prescribing controls. Several states have enacted additional restrictions; some jurisdictions have banned or limited pharmacy dispensing of combination opioids.
Industry trends reflect increasing restrictions. In 2016, the CDC issued guidelines to reduce opioid prescriptions[1]. These measures lead to reduced availability and prescribing of drugs like TYLENOL W/ CODEINE NO. 2, impacting market size and revenue.
What are the key drivers affecting sales and revenue?
Prescribing Trends
A significant decline in prescriptions stems from increased awareness of opioid addiction and government efforts to curb misuse. Data from IQVIA indicates a 30% decline in codeine combination prescriptions in the US from 2015 to 2020[2].
Off-Label Use and Abuse Concerns
The potential for misuse contributes to regulatory restrictions. Abuse-deterrent formulations are under development but are not yet widespread for this class. Prescribers favor alternative treatments, such as NSAIDs or non-opioid analgesics, further reducing the drug's market share.
Patent and Patent Expirations
The original formulation's patent has long expired. Since then, generic manufacturers dominate the market, leading to a significant reduction in branded sales.
What is the financial trajectory for TYLENOL W/ CODEINE NO. 2?
Sales Figures
Detailed sales data are limited publicly. However, recent estimates suggest a decline from peak revenues of approximately $150 million in 2010 to roughly $30 million in 2021 in the US[3]. The loss of patent protection and increased regulation contribute to this decline.
Market Share
The drug's market share has dropped from over 5% of combination opioid analgesics in 2010 to below 1% in recent years[2].
Future Trends
Projections indicate continued decline unless new formulations or indications emerge. The increasing rarity of prescriptions and regulatory barriers suggest a gradual phasing out.
Competitive Landscape
Generic manufacturers hold about 90% of the market, with minor players producing alternative opioids. Non-opioid analgesics, including NSAIDs and acetaminophen alone, have absorbed market share.
What are the potential opportunities and risks?
Opportunities
- Development of abuse-deterrent formulations.
- Repurposing for alternative indications where opioids are still viable.
- Export markets with less restrictive regulations.
Risks
- Regulatory bans or tightening.
- Growing public and legislative opposition to opioids.
- Competition from non-opioid pain medications.
What is the regulatory outlook?
The FDA has issued warnings and reinforced strict prescribing guidelines for opioids, including TYLENOL W/ CODEINE NO. 2. Recent moves aim at reducing opioid use, with some states implementing bans on codeine-containing products in children under 12[4].
Key Takeaways
- Prescribing of TYLENOL W/ CODEINE NO. 2 has declined sharply due to regulatory restrictions and the opioid epidemic.
- The drug's market share has diminished, with revenues falling significantly since 2010.
- Industry trends point toward further reductions unless new formulations or indications are developed.
- Regulatory environment tightens, entrenching risks for sustained or increased sales.
- Generic manufacturing dominates the market, limiting profitability for branded versions.
FAQs
1. What factors led to the decline of TYLENOL W/ CODEINE NO. 2?
Prescribing restrictions, opioid misuse concerns, and the availability of safer alternatives reduced demand.
2. Are there any upcoming regulatory changes that could impact this drug?
Further restrictions are anticipated, especially on prescribing practices and state-level bans.
3. Is there potential for new formulations of TYLENOL W/ CODEINE NO. 2?
Development of abuse-deterrent formulations is underway but not yet commercialized, offering limited near-term opportunities.
4. How does the market for TYLENOL W/ CODEINE NO. 2 compare internationally?
Many countries have banned or restricted codeine combination products, reducing global demand.
5. What is the outlook for the generic manufacturers?
They benefit from low production costs and the absence of patent restrictions, but declining overall market size constrains revenues.
References
[1] Centers for Disease Control and Prevention. (2016). CDC Guideline for Prescribing Opioids for Chronic Pain.
[2] IQVIA. (2021). Prescription Trends for Opioids.
[3] MarketWatch. (2022). US Pain Management Drugs Market Analysis.
[4] U.S. Food and Drug Administration. (2020). Guidance on Opioid Prescribing in Children.
